World Bulletin / News Desk
South Africa on Wednesday begins a major clinical trial of an experimental vaccine against AIDS, which scientists hope could be the "final nail in the coffin" for the disease.
More than 30 years of efforts to develop an effective vaccine for HIV have not borne fruit, but for the first time since the virus was identified in 1983, scientists think they have found a promising candidate.
The new study, known as HVTN 702, will involve more than 5,400 sexually active men and women aged 18-35 in 15 areas around South Africa over four years.
"If deployed alongside our current armoury of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV," said Anthony Fauci, director of the US National institute for Allergies and Infectious Diseases (NIAID), which is taking part in the study.
"Even a moderately effective vaccine would significantly decrease the burden of HIV disease over time in countries and populations with high rates of HIV infection, such as South Africa."
South Africa was not chosen by accident for the trial. The country has one of the highest rates of HIV infection in the world -- 19.2 percent according to the UN AIDS agency, or more than seven million people living with the virus.
Each year some two and a half million people around the world are infected with HIV, which has killed more than 30 million people since the 1980s, according to a study presented at a conference in South Africa in July.
The vaccine has been adapted for the HIV strain prevalent in southern Africa from one used in a trial of 16,000 people in Thailand in 2009, which reduced the risk of infection by over 30 percent three and a half years after the first vaccination.
The safety of the "South African" vaccine has already been tested successfully over 18 months on 252 volunteers. The new study aims to test its effectiveness.
"The results obtained in Thailand are not good enough for a roll-out (...) we have set the minimum bar at 50 percent," Lynn Morris, head of the HIV virology section at South Africa's National Institute for Communicable Disease (NICD), told AFP.
South Africa's Deputy President Cyril Ramaphosa told parliament earlier this month that "scientists expect the (new) vaccine to be at least 50 percent effective but hope that it will be much higher".
But despite the hopes raised by the new vaccine, experts warn it is vital to remain vigilant in the fight against HIV.
"A highly efficient vaccine would be a game-changer but the results of these trials will take years," Morris said.
"We must continue to use other HIV prevention tools to reduce the number of new HIV infections, particularly in vulnerable populations such as young women, who continue to be most heavily affected."
For now antiretroviral (ARV) treatments remain by far the most effective tool against HIV.
According to UNAIDS, half of the 36 million or so people with HIV around the world have access to ARVs, a figure that has doubled in five years.
Thanks to these treatments, which control the virus and increase the lifespan of HIV-positive people, average ife expectancy in South Africa has risen from 57.1 years to 62.9 since 2009, according to local authorities.
The new trial is being carried out by the US National Institutes of Health, the South African Medical Research Council, the Bill and Melinda Gates Foundation, Sanofi Pasteur, GlaxoSmithKline and the HIV Vaccine Trials Network.
More than 100,000 people -- half of them children -- die every year due to waterborne diseases, experts say
Located in the bustling Adjame quarter of Ivory Coast's main city and commercial hub, the haven for fake medicine has been targeted time and again by authorities and stockpiles burnt.
Seven firms to receive ecolabel certifying that their products are environment-friendly
Disasters saddle U.S. with $306 billion price tag, cause 362 deaths
Association for Prevention of Drug Abuse head says close to more than 2.5 million children are drug addicts in Bangladesh
King penguins are certainly accustomed to chilly weather, more so than species like the Humboldt that prefer somewhat warmer climes, said zoo curator Malu Celli.
Some eight million children and teenagers across the Southeast Asian nation will receive the shot to prevent further spread of the disease which is caused by a bacterial infection.
Two players vomited on the pitch, and play had to be halted briefly.
French pharmaceutical giant Sanofi announced Wednesday that its world-first dengue vaccine could lead to more severe symptoms for people who had not previously been infected.
Doctors Worldwide Turkey says it has performed 3,000 cataract surgeries in Horn of Africa country
Over 40,000 cases of cholera seen in Democratic Republic of Congo since July, says Health Ministry
Decked out in red to signify their "Stop Coal" campaign, the protesters chanted and beat drums as they snaked through the former West Germany capital toward the UN centre that will host the 12-day, 196-nation talks, tasked with implementing the landmark Paris Agreement.
The Greenhouse Gas Bulletin, the UN weather agency's annual flagship report, tracks the continent of dangerous gasses in atmosphere in the post-industrial era (since 1750).
£10 ($13) tax introduced to cut British capital's poor air-pollution records
Despite all-out efforts to give the Chinese Communist Party blue skies for its twice-a-decade congress, Beijing's notorious smog has cloaked the mega-city in its trademark toxic haze.
Equipment donation to children's oncology institute is first project of state-run aid agency TIKA in Brazil